Haemonetics Corporation Company Profile (NYSE:HAE)

About Haemonetics Corporation

Haemonetics Corporation logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NYSE
  • Symbol: HAE
  • CUSIP: 40502410
Key Metrics:
  • Previous Close: $37.50
  • 50 Day Moving Average: $39.06
  • 200 Day Moving Average: $37.75
  • 52-Week Range: $25.98 - $41.65
  • Trailing P/E Ratio: 119.43
  • Foreward P/E Ratio: 23.58
  • P/E Growth: 2.98
  • Market Cap: $1.95B
  • Outstanding Shares: 52,004,000
  • Beta: 0.92
Profitability:
  • Net Margins: 1.79%
  • Return on Equity: 10.51%
  • Return on Assets: 5.89%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 2.30%
  • Quick Ratio: 1.42%
Additional Links:
Companies Related to Haemonetics Corporation:

Analyst Ratings

Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $34.57 (7.81% downside)

Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
Show:
DateFirmActionRatingPrice TargetDetails
2/7/2017Barrington ResearchDowngradeOutperform -> Market PerformView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralView Rating Details
11/7/2016Benchmark Co.Boost Price TargetHold$32.00 -> $34.00View Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00View Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00View Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00View Rating Details
8/2/2016Jefferies Group LLCBoost Price TargetBuy$32.00 -> $40.00View Rating Details
5/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$29.00View Rating Details
5/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformView Rating Details
11/23/2015Raymond James Financial, Inc.DowngradeMarket Perform -> UnderperformView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Haemonetics Corporation (NYSE:HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.52$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.15$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.46$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.36$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Haemonetics Corporation (NYSE:HAE)
Current Year EPS Consensus Estimate: $1.52 EPS
Next Year EPS Consensus Estimate: $1.59 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.43$0.49$0.46
Q2 20163$0.25$0.33$0.29
Q3 20164$0.40$0.46$0.44
Q4 20164$0.48$0.57$0.54
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.37$0.42$0.39
Q4 20173$0.35$0.38$0.36
Q1 20182$0.23$0.30$0.27
Q2 20182$0.44$0.46$0.45
Q3 20182$0.42$0.46$0.44
Q4 20182$0.37$0.41$0.39
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Haemonetics Corporation (NYSE:HAE)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 99.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.90View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Haemonetics Corporation (NYSE:HAE)
DateHeadline
openpr.com logoGlobal Apheresis Equipment Market to Expand at 11.30% CAGR 2012-2018 owing to Rising Demand for Plasma (NYSE:HAE)
www.openpr.com - February 23 at 10:37 PM
News IconNew report examines the apheresis market to 2021 (NYSE:HAE)
www.whatech.com - February 23 at 5:35 PM
News IconGlobal Platelet Aggregation Devices Market to register USD 427.0 million growth by 2022 (NYSE:HAE)
www.medgadget.com - February 23 at 5:35 PM
sbwire.com logoPlatelet Aggregation Devices Market Research Report by Regional Analysis: Forecast 2023 (NYSE:HAE)
www.sbwire.com - February 23 at 5:35 PM
finance.yahoo.com logoHAEMONETICS CORP Financials (NYSE:HAE)
finance.yahoo.com - February 10 at 6:19 PM
capitalcube.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: Q3, 2017 By the Numbers : February 9, 2017 (NYSE:HAE)
www.capitalcube.com - February 9 at 6:28 PM
finance.yahoo.com logoQuotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer (NYSE:HAE)
finance.yahoo.com - February 9 at 6:28 PM
biz.yahoo.com logoHAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NYSE:HAE)
us.rd.yahoo.com - February 8 at 6:15 PM
us.rd.yahoo.com logoHaemonetics downgraded by Barrington Research (NYSE:HAE)
us.rd.yahoo.com - February 7 at 11:56 PM
seekingalpha.com logoHaemonetics (HAE) Q3 2017 Results - Earnings Call Transcript (NYSE:HAE)
seekingalpha.com - February 7 at 3:40 AM
biz.yahoo.com logoHaemonetics Corp Earnings Call scheduled for 8:00 am ET today (NYSE:HAE)
biz.yahoo.com - February 6 at 10:39 PM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 6-Feb-17 1:00pm GMT (NYSE:HAE)
finance.yahoo.com - February 6 at 10:39 PM
us.rd.yahoo.com logoHaemonetics 3rd Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website (NYSE:HAE)
us.rd.yahoo.com - February 6 at 5:39 PM
us.rd.yahoo.com logo6:11 am Haemonetics beats by $0.03, beats on revs; raises FY17 EPS and revs outlook to high end of previous guidance (NYSE:HAE)
us.rd.yahoo.com - February 6 at 5:39 PM
biz.yahoo.com logoQ3 2017 Haemonetics Corp Earnings Release - 06:00 am ET (NYSE:HAE)
us.rd.yahoo.com - February 6 at 5:39 PM
finance.yahoo.com logoHaemonetics tops Street 3Q forecasts (NYSE:HAE)
finance.yahoo.com - February 6 at 10:54 AM
seekingalpha.com logoHaemonetics Corp 2017 Q3 - Results - Earnings Call Slides (NYSE:HAE)
seekingalpha.com - February 6 at 10:54 AM
News IconResearch report covers the Platelet Function Test Market share and Growth, 2016-2026 (NYSE:HAE)
www.medgadget.com - February 3 at 6:08 PM
News IconCould Haemonetics Corporation (HAE) Change Direction After Touching 52-Week High? (NYSE:HAE)
randolphguide.com - February 3 at 6:08 PM
finance.yahoo.com logoMedical Product Stocks' Earnings on Feb 6: HAE, PAHC & More (NYSE:HAE)
finance.yahoo.com - February 3 at 6:08 PM
capitalcube.com logoETFs with exposure to Haemonetics Corp. : February 3, 2017 (NYSE:HAE)
www.capitalcube.com - February 3 at 6:08 PM
capitalcube.com logoHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : February 2, 2017 (NYSE:HAE)
www.capitalcube.com - February 2 at 6:15 PM
News IconNew Trends of Hemostasis Testing Systems Market Analysis to 2026 (NYSE:HAE)
reports.pr-inside.com - January 30 at 6:19 PM
openpr.com logoPhotopheresis Products Market : New Tech Developments And Advancements To Watch Out For 2024!! (NYSE:HAE)
www.openpr.com - January 27 at 7:31 PM
News IconBlood Collection Processing, Management Devices & Consumables Global Market Estimated to be Worth $35,693 Million by 2023 (NYSE:HAE)
www.pr.com - January 27 at 7:31 PM
sbwire.com logoBlood Collection, Processing, Management Devices and Consumables Market Is Expected to Reach $35,693 Million by 2023; Finds New Report (NYSE:HAE)
www.sbwire.com - January 25 at 6:59 PM
News IconTherapeutic Plasma Exchange Market - Future Trends and Forecast 2016 - 2024 (NYSE:HAE)
reports.pr-inside.com - January 23 at 9:03 PM
finance.yahoo.com logoBlood Collection, Processing, Management Devices & Consumables Global Market - Forecast To 2023 (NYSE:HAE)
finance.yahoo.com - January 23 at 9:03 PM
einnews.com logoBlood Collection, Processing, Management Devices & Consumables Global Market Analysis and Forecast to 2023 (NYSE:HAE)
www.einnews.com - January 23 at 4:02 PM
capitalcube.com logoHaemonetics Corp. – Value Analysis (NYSE:HAE) : January 19, 2017 (NYSE:HAE)
www.capitalcube.com - January 19 at 7:23 PM
capitalcube.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : January 18, 2017 (NYSE:HAE)
www.capitalcube.com - January 18 at 6:02 PM
finance.yahoo.com logoHaemonetics Sets Date for 3rd Quarter Fiscal 2017 Earnings Release: February 6, 2017 (NYSE:HAE)
finance.yahoo.com - January 17 at 8:37 PM
News IconGlobal Plasmapheresis Machines Market Professional Survey Report 2017 ... (NYSE:HAE)
www.medgadget.com - January 13 at 11:49 PM
News IconThe global apheresis market is expected to reach USD 2.5 billion according to new research report (NYSE:HAE)
www.whatech.com - January 6 at 6:13 PM
News IconNorth America Disposable Plastic Blood Bag Market is Expected to Witness Fastest Growth (9.4% CAGR) During 2015 – 2020 (NYSE:HAE)
www.abnewswire.com - January 6 at 6:13 PM
openpr.com logoApheresis Equipment Market Research Report by Plasmapheresis, Photopheresis, Apheresis in Neurological, Renal, Hematological Diseases (NYSE:HAE)
www.openpr.com - January 3 at 11:53 AM
News IconBlood Processing Devices and Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 (NYSE:HAE)
reports.pr-inside.com - January 3 at 11:53 AM
finance.yahoo.com logoHaemonetics to Present at 35th Annual J.P. Morgan Health Care Conference (NYSE:HAE)
finance.yahoo.com - January 3 at 11:53 AM
seekingalpha.com logoHaemonetics: Investor Patience Is Wearing Thin (NYSE:HAE)
seekingalpha.com - December 20 at 10:44 PM
News IconGlobal Apheresis Machine for Plasmapheresis Market 2016 - Haemonetics Corporation, Fresenius Medical Care (NYSE:HAE)
www.mynewsdesk.com - December 17 at 4:15 AM
stocksdaily.net logoCan Haemonetics Corporation (NYSE:HAE) Meet Analysts EPS Target Of $0.4? (NYSE:HAE)
www.stocksdaily.net - December 14 at 11:20 PM
finance.yahoo.com logoHaemonetics' Plasma Group Impresses, Blood Center a Drag (NYSE:HAE)
finance.yahoo.com - December 13 at 10:49 AM
insidermonkey.com logoShould You Avoid Haemonetics Corporation (HAE)? (NYSE:HAE)
www.insidermonkey.com - December 9 at 10:14 AM
finance.yahoo.com logoHaemonetics Introduces Upgraded NextGen DMS 4 Software (NYSE:HAE)
finance.yahoo.com - December 9 at 10:14 AM
reuters.com logoBRIEF-Haemonetics Corp announces release of Nextgen DMS 4 (NYSE:HAE)
www.reuters.com - December 8 at 10:52 AM
finance.yahoo.com logoHaemonetics Announces the Release of NextGen DMS 4 (NYSE:HAE)
finance.yahoo.com - December 8 at 10:52 AM
finance.yahoo.com logoMedTech Sails Through Macro Woes: Stocks in Focus (NYSE:HAE)
finance.yahoo.com - December 2 at 5:29 PM
News IconGlobal Apheresis Equipment Market 2016 by Haemonetics Corporation, Therakos, NIKKISO, Macopharma to 2021 (NYSE:HAE)
www.mynewsdesk.com - November 30 at 9:18 AM
4-traders.com logoHaemonetics : MILITARY $28,576 Federal Contract Awarded to Haemonetics (NYSE:HAE)
www.4-traders.com - November 29 at 4:51 PM
4-traders.com logoHaemonetics : MILITARY $28,576 Federal Contract Awarded to Haemonetics (NYSE:HAE)
www.4-traders.com - November 29 at 4:51 PM

Social

What is Haemonetics Corporation's stock symbol?

Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?

9 brokerages have issued 12 month target prices for Haemonetics Corporation's shares. Their forecasts range from $24.00 to $41.00. On average, they expect Haemonetics Corporation's stock price to reach $34.57 in the next twelve months.

When will Haemonetics Corporation announce their earnings?

Haemonetics Corporation is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

Who owns Haemonetics Corporation stock?

Haemonetics Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.25%), State Street Corp (2.27%), Franklin Resources Inc. (1.92%), Renaissance Technologies LLC (1.72%), Martingale Asset Management L P (0.35%) and FMR LLC (0.34%). Company insiders that own Haemonetics Corporation stock include Brian Concannon, Byron Selman, Christopher J Lindop, Christopher Simon, Jonathan White, Peter M Allen, Ronald G Gelbman, Ronald Merriman, Sandra Jesse, Susan Bartlett Foote and Susan M Hanlon.

Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?

Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, AQR Capital Management LLC, State Board of Administration of Florida Retirement System, Metropolitan Life Insurance Co. NY, Systematic Financial Management LP and Teachers Retirement System of The State of Kentucky. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman.

Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?

Haemonetics Corporation's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Martingale Asset Management L P, Cigna Investments Inc. New, Tudor Investment Corp Et Al, Renaissance Technologies LLC, Numeric Investors LLC and Bayesian Capital Management LP.

How do I buy Haemonetics Corporation stock?

Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Haemonetics Corporation stock cost?

One share of Haemonetics Corporation stock can currently be purchased for approximately $37.50.

Haemonetics Corporation (NYSE:HAE) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Earnings History Chart

Earnings by Quarter for Haemonetics Corporation (NYSE:HAE)

Dividend History Chart

Dividend Payments by Quarter for Haemonetics Corporation (NYSE:HAE)

Last Updated on 2/23/2017 by MarketBeat.com Staff